<DOC>
	<DOCNO>NCT00066989</DOCNO>
	<brief_summary>The main objective test safety two intravenous infusion Altastaph , human immunoglobulin product . The study also test ability Altastaph protect S. aureus infection .</brief_summary>
	<brief_title>Safety Study Intravenous Staphylococcus Aureus Immune Globulin ( Human ) , Altastaph Low-Birth-Weight-Neonates</brief_title>
	<detailed_description>Survival Very-Low-Birth-Weight ( VLBW ) infant ( &lt; 1500g birth ) improve dramatically , patient remain subject significant morbidity mortality due Staphylococcus aureus infection . S. aureus infection relatively common event VLBW neonates , occur approximately 3.4 % low birth weight neonates account 15-20 % infection patient population . This control study ass safety , pharmacokinetics , preliminary efficacy Altastaph LBW neonates . The study stratify birth weight include 200 LBW neonate , 3 7 day age .</detailed_description>
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>The subject must conform follow ( Inclusion Criteria ) : Neonate birth weight 501 1500 gram inclusive ; Between 3 7 day age , inclusive , time first infusion ( Day 0 ) ; Expected survive least 48 hour infusion ; Free overt systemic infection , determine history , physical examination , radiologic study , laboratory study include microbiology data ; clinical safety test require complete three ( 3 ) day prior infusion study product ; Direct bilirubin less equal 2.0 mg/dL ; Serum creatinine level less equal 2.0 mg/dL ; Hemodynamically stabile ; subject receive cardiac support include antiarrhythmic , pressor , cardiac pacing , subject must stable cardiac support expect require support indefinitely . The subject must follow ( Exclusion Criteria ) : Known HIV infection , document maternal history positive PCR infant ; Severe congenital anomaly genetic disorder know impact immune competence ; Prior administration immune globulin ; Any history , infant subject mother , hypersensitivity severe vasomotor reaction human blood product ; Cyanotic congenital heart disease ; Central nervous system shunt</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Days</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Staphylococcal infection</keyword>
	<keyword>Gram positive bacteria</keyword>
	<keyword>Staphylococcus</keyword>
	<keyword>Staphylococcus aureus</keyword>
</DOC>